Loading patent…
AssigneeArgos Therapeutics, Inc.
InventorIrina Tcherepanova
Estimating the term…
The invention relates to improved methods and compositions for the nucleic acid amplification of one or multiple variants (strains) of Human Immunodeficiency Virus (HIV) present in a sample, and preferably in a sample from a pathogen infected individual. In particular, novel primers, methods and kits for the amplification of one or more species of HIV Rev, Gag and Nef nucleic acids are provided. The amplified HIV nucleic acid can be used to identify and/or quantitate HIV variants present in a sample. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can also be used directly as vaccines or to transfect/load antigen presenting cells. The loaded antigen presenting cells can be used as a vaccine for the treatment or prevention of HIV infection.
A composition comprising at least one or a combination of Rev T7 promoter primers selected from the group consisting of:
A composition comprising a Gag reverse primer selected from the group consisting of SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:48, or any combination thereof.
A Nef forward primer composition comprising the NEF forward primer F8235.2 of SEQ ID NO:58.
A method for amplifying an HIV Rev nucleic acid, comprising carrying out a polymerase chain reaction using at least one or a combination of Rev T7 7912 forward primers selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28 and SEQ ID NO:29;
A method for amplifying an HIV Gag nucleic acid, comprising carrying out a polymerase chain reaction using at least one or a combination of Gag forward primers selected from the group consisting of SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33;
A method for amplifying an HIV Nef nucleic acid, comprising carrying out a polymerase chain reaction using at the Nef F8235 forward primers of SEQ ID NO:49, SEQ ID NO:50 and SEQ ID NO:58, together with and at least one or a combination of Nef R9069 reverse primers selected from the group consisting SEQ ID NO:55, SEQ ID NO:56 and SEQ ID NO:57.
Dependencies are inferred from the claim text.